Scorpius Holdings Inc. · OTC:SCPX
Scorpius — Heat Biologics — Phacilitate Immunotherapy World Conference 2016
5 slides from Scorpius's conference presentation, Jan 27, 2016
Slide 1: Phacilitate Immunotherapy World Conference January 26, 2016
Phacilitate Immunotherapy World Conference January 26, 2016
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes statements that are, or may be deemed, ‘‘forward-looking statements.’’ In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expec
Slide 3: HS-410 Ph 2 NMIBC Trial Overview
HS-410 Ph 2 NMIBC Trial Overview 3 Objective Evaluate safety and tolerability of HS-410 either alone or in combination with BCG Patient Population 100 patients with NMIBC (high-grade Ta; T1; CIS) after TURBT Enrollment 16 U.S. sitesCompleted enrollment of 75 randomized patients; enrolling 25 patient
Slide 4: HS-410 Ph 2 NMIBC Monotherapy 3-Month Interim Data
HS-410 Ph 2 NMIBC Monotherapy 3-Month Interim Data 3-mo recurrence rates (RR) – combo arms still blinded 4 Population Historical RR1 Monotherapy RR High-risk papillary only ~20% 1/6 (17%) CIS ~50% 0/1 (0%) Intermediate risk UNK (~<20%) N/A Composite ~30% 1/7 (14%) Source: 1) SWOG 8507 (Lamm 2000 J.U
Slide 5: HS-410 Ph 2 NMIBC Monotherapy 3-Month Interim Data
HS-410 Ph 2 NMIBC Monotherapy 3-Month Interim Data Images of the bladder (above) showed changes that resemble lymphoid (T cell rich) structures, indicating that HS-410 leads to a localized immune response within the urinary bladder 5 Blue-light cystoscopy from patient treated with HS-410 Tumor biops
Heat Biologics — Phacilitate Immunotherapy World Conference 2016 on 6ix